Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) leads to improved survival compared with ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

As ICSs treat COPD exacerbations, people on ICSs could have fewer coded ... Second, an important question arising from this research is whether medication response is influenced by demographics or ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for exceptional importation and sale are called "designated drugs".

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...